Vor Biopharma Inc. (NYSE:VOR) Receives $11.36 Average Target Price from Analysts

Vor Biopharma Inc. (NYSE:VOR) has been assigned an average recommendation of “Buy” from the seven brokerages that are currently covering the firm, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $11.36.

A number of research analysts have commented on the company. Wedbush reiterated an “outperform” rating and issued a $11.00 price objective on shares of Vor Biopharma in a research report on Monday, December 9th. Robert W. Baird decreased their price objective on Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th. HC Wainwright reiterated a “buy” rating and issued a $17.50 price objective on shares of Vor Biopharma in a research report on Tuesday, December 10th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $12.00 price objective on shares of Vor Biopharma in a research report on Tuesday, December 10th.

Vor Biopharma Price Performance

VOR stock opened at $1.37 on Friday. The business has a fifty day moving average price of $1.00 and a 200 day moving average price of $0.91. Vor Biopharma has a fifty-two week low of $0.63 and a fifty-two week high of $2.59. The stock has a market capitalization of $94.08 million, a price-to-earnings ratio of -0.83 and a beta of -0.51.

Vor Biopharma (NYSE:VOR) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.40) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.40). On average, equities analysts expect that Vor Biopharma will post -1.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Rosalind Advisors Inc. bought a new position in Vor Biopharma during the third quarter worth about $54,000. Exchange Traded Concepts LLC lifted its holdings in Vor Biopharma by 40.8% during the third quarter. Exchange Traded Concepts LLC now owns 165,805 shares of the company’s stock worth $116,000 after acquiring an additional 48,017 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in Vor Biopharma during the second quarter worth about $53,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Vor Biopharma during the second quarter worth about $63,000. Finally, Hsbc Holdings PLC lifted its holdings in Vor Biopharma by 177.0% during the second quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock worth $51,000 after acquiring an additional 31,333 shares in the last quarter. 97.29% of the stock is currently owned by institutional investors.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.